Logo

ArcherDx VariantPlex Core Myeloid Panel

Aug 02, 2017

ArcherDx has launched the Archer VariantPlex Core Myeloid panel, a next-generation sequencing-based targeted panel that analyzes 37 genes related to myeloid malignancies. The company said the panel uses molecular barcoded reads, and can detect FLT3 internal tandem duplications, variants that are present in more than 20 percent of acute myeloid leukemia cases and are challenging to detect in NGS data. VariantPlex assays are provided in eight-strip, single-use lyophilized library preparation reagents that require no master mixes.

ArcherDx said that it also plans to launch a VariantPlex Myeloid panel, which expands the number of genes to 72.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.